JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB258077

Human NMI (N myc interactor/NMI) knockout A549 cell lysate

Be the first to review this product! Submit a review

|

(0 Publication)

NMI KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 2 bp deletion in exon5 and 330 bp insertion in exon5.

View Alternative Names

N myc (and STAT) interactor, N myc and STAT interactor, N myc interactor

3 Images
Western blot - Human NMI (N myc interactor/NMI) knockout A549 cell lysate (AB258077)
  • WB

Lab

Western blot - Human NMI (N myc interactor/NMI) knockout A549 cell lysate (AB258077)

Lane 1 : Wild-type A549 (Human lung carcinoma cell line) whole cell lysate (20 ug)
Lane 2 : NMI knockout A549 (Human lung carcinoma cell line) whole cell lysate (20 ug)
Lane 3 : HeLa (Human epithelial cell line from cervix adenocarcinoma) whole cell lysate (20 ug)
Lane 4 : K562 (Human chronic myelogenous leukemia lymphoblast cell line ) whole cell lysate (20 ug)

ab183724 was shown to specifically react with N myc interactor/NMI in wild-type A549 cells. Loss of signal was observed when knockout cell line ab267013 (knockout cell lysate ab258077) was used. Wild-type and N myc interactor/NMI knockout samples were subjected to SDS-PAGE. ab183724 and Anti-GAPDH antibody [6C5] - Loading Control (ab8245) were incubated overnight at 4oC at 1 in 1000 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.

All lanes:

Western blot - Anti-N myc interactor/NMI antibody [EPR11065(2)] (<a href='/en-us/products/primary-antibodies/n-myc-interactor-nmi-antibody-epr110652-ab183724'>ab183724</a>) at 1/1000 dilution

Lane 1:

Wild-type A549 (Human lung carcinoma cell line) whole cell lysate at 20 µg

Lane 2:

NMI knockout A549 (Human lung carcinoma cell line) whole cell lysate at 20 µg

Lane 2:

Western blot - Human NMI (N myc interactor/NMI) knockout A549 cell line (<a href='/en-us/products/cell-lines/human-nmi-n-myc-interactor-nmi-knockout-a549-cell-line-ab267013'>ab267013</a>)

Lane 3:

HeLa (Human epithelial cell line from cervix adenocarcinoma) whole cell lysate at 20 µg

Lane 4:

K562 (Human chronic myelogenous leukemia lymphoblast cell line ) whole cell lysate at 20 µg

Secondary

All lanes:

Western blot - Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-irdye-800cw-preadsorbed-ab216773'>ab216773</a>) at 1/10000 dilution

Predicted band size: 35 kDa

Observed band size: 39 kDa

false

Sanger Sequencing - Human NMI (N myc interactor/NMI) knockout A549 cell lysate (AB258077)
  • Sanger seq

Unknown

Sanger Sequencing - Human NMI (N myc interactor/NMI) knockout A549 cell lysate (AB258077)

Allele-2 : 330 bp insertion in exon5

Sanger Sequencing - Human NMI (N myc interactor/NMI) knockout A549 cell lysate (AB258077)
  • Sanger seq

Unknown

Sanger Sequencing - Human NMI (N myc interactor/NMI) knockout A549 cell lysate (AB258077)

Allele-1 : 2 bp deletion in exon5

Key facts

Cell type

A549

Species or organism

Human

Tissue

Lung

Knockout validation

Sanger Sequencing,Western blot

Mutation description

Knockout achieved by using CRISPR/Cas9, 2 bp deletion in exon5 and 330 bp insertion in exon5.

Disease

Carcinoma

style
left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "WB": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }
style
left-column

Product details

Knockout cell lysate achieved by CRISPR/Cas9.

REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.

User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

style
left-column

What's included?

{ "values": { "1Kit": { "sellingSize": "1 Kit", "publicAssetCode":"ab258077-1Kit", "assetComponentDetails": [ { "size":"1 x 100 µg", "name":"Human NMI knockout A549 cell lysate", "number":"AB258077-CMP02", "productcode":"" }, { "size":"1 x 100 µg", "name":"Human wild-type A549 cell lysate", "number":"AB258077-CMP01", "productcode":"" } ] } } }
style
left-column

Properties and storage information

Gene name
NMI
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing, Western blot
Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C
style
left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

N myc interactor often referred to as NMI interacts with members of the MYC family including N-MYC and C-MYC. Known as N-MYC and C-MYC interacting protein NMI has a molecular weight of approximately 54 kDa. NMI expresses in a variety of tissues with higher levels in brain and liver tissues. Its presence is also notable in immune cells pointing towards a complex role in cellular processes related to both developmental and immune responses.
Biological function summary

NMI collaborates with transcription factors to influence the regulation of gene expression. It plays a significant role in the formation of protein complexes that regulate transcriptional activities of oncogenes particularly through interaction with MYC and STAT proteins. NMI's ability to form complexes makes it a notable player in modulating signal transduction pathways. Its balancing act with transcription factors affects cell proliferation and differentiation critical components of its biological functionality.

Pathways

NMI has a significant impact on the JAK-STAT signaling pathway and the MYC-mediated transcription network. Within these pathways NMI modulates the activities of the MYC family of oncogenes and interacts with signal transducers and activators like STATs. These interactions contribute to the regulation of cellular processes such as growth and apoptosis. Such pathways illustrate NMI's role in maintaining cellular homeostasis and its interactive role with proteins like STAT and MYC.

NMI has been associated with cancer and autoimmune diseases. NMI's interaction with MYC oncogenes links it to various cancers particularly neuroblastoma. It also associates with autoimmune disorder mechanisms implicating its expression and regulation in immune-related pathologies. In cancer NMI's relationship with MYC affects tumor growth and progression illustrating its potential as a target for therapeutic intervention. Its involvement highlights the importance of understanding its function in disease pathways.
style
left-column

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

style
left-column

Cell culture

Biosafety level

EU: 1 US: 1

Adherent/suspension

Adherent

Gender

Male

style
left-column

Product protocols

style
left-column
style
left-column
style
right-column

Complementary Products

Primary Antibodies

AB183724

Anti-N myc interactor/NMI antibody [EPR11065(2)]

RabMAb|Recombinant|KO Validated

Western blot - Anti-N myc interactor/NMI antibody [EPR11065(2)] (AB183724)

  • 0
  • 0
Proteins & Peptides

AB103504

Recombinant Human N myc interactor/NMI protein

SDS-PAGE - Recombinant Human N myc interactor/NMI protein (AB103504)

  • 0
  • 0

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com